Home Blog Page 68

GAC Wins 8 Awards, Including 4 First Prizes, Showcasing Technological Innovation Strength

SUZHOU, China, Oct. 31, 2026 /PRNewswire/ — On October 28, GAC won 8 awards at the 2026 China-SAE Science and Technology Award ceremony in Suzhou, Jiangsu. In the fields of automotive chips, electric drive, vehicle safety, intelligent driving governance and body design, four first prizes were awarded to two GAC-led projects and two GAC-participated projects, and one GAC-led project won second prize.

GAC Wins 8 Awards, Including 4 First Prizes, Showcasing Technological Innovation Strength
GAC Wins 8 Awards, Including 4 First Prizes, Showcasing Technological Innovation Strength

In chips, GAC’s led project built a full-chain path from vehicle definition to scale application, working with 105 partners to apply nearly 400 chip models and over 1,000 domestic chips. The HYPTEC GT Special Edition, China’s first ICV with 100% domestically designed chips, has been launched.

In electric drive, GAC pioneered mass production of amorphous alloy stators and carbon-fiber high-speed rotors, becoming the world’s only company to mass-produce amorphous alloy automotive motors. Its amorphous ribbon is just 0.025 mm thick. The motor reaches 99.03% peak efficiency, 17.29 kW/kg power density (@1000V)—nearly three times the industry mainstream—and 30,000 rpm maximum speed; system CLTC efficiency reaches 94.184%. For users, energy consumption drops 4%, and range rises 30-50 km with the same battery capacity. It has been applied to HYPTEC, AION and AISTALAND models and promoted to other automakers. The related precision manufacturing technology won the Gold Medal with Congratulations of the Jury at the 51st International Exhibition of Inventions of Geneva.

In safety, the GAC-led project with Tsinghua University won second prize. It developed China’s first ASIL-D fully domestic safety controller, real-time risk quantification, active-suspension side-impact mitigation, a rear-window airbag and an “automaker-traffic police-hospital” integrated rescue model. It has been applied to 20 models with cumulative sales of 1.446 million units.

In addition, GAC’s participated L2-L4 safety governance project helped establish a full-lifecycle system covering pre-admission, in-process supervision and post-event traceability. Its participated BIW project features an AI-based body design system that generates concept schemes within 5 hours, with over 95% stiffness prediction accuracy and over 30% higher design efficiency; it has been applied to the second-generation GAC GS8, GAC ES9 and GAC All-new S7.

Looking ahead, GAC will uphold innovation-driven development, advance core technology breakthroughs and commercialization, and support high-quality development of China’s auto industry.

For further information about GAC, please visit: https://www.gacgroup.com/en or follow us on social.

Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

SHANGHAI, Oct. 31, 2026 /PRNewswire/ — Shanghai Zhimeng Biopharma, Inc. ( “Zhimeng Biopharma”) announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfully completed patient enrollment in its pivotal Phase 2/3 clinical trial, in total enrolled 255 patients. This significant milestone marks the entry of the critical stage in the clinical development of CB03-154 for ALS in China, laying a solid foundation for the upcoming analysis of topline data and potential new drug application submissions.

This pivotal clinical trial has been conducted in China, with Professor Fan Dongsheng from the 3rd Affiliated Hospital of Peking University serving as the national leading principal investigator (Leading PI), and involving a total of 15 clinical research centers in Mainland China. The study aims to evaluate the efficacy and safety of CB03-154 in patients with ALS, with the primary efficacy endpoint being the change from baseline in the ALSFRS‑R score at Week 39. Previously, CB03-154 received approval from the China CDE in July 2025 to initiate Phase 2/3 clinical trials for ALS, and in October 2023 it was granted Orphan Drug Designation (ODD) by the U.S. FDA.

As a rare disease, ALS poses numerous unique challenges in drug development. Notably, based on the current clinical progress, if the Phase 2 topline results are positive in the third quarter of 2027, Zhimeng Biopharma plans to submit a marketing application to the China CDE for a conditional approval. This strategy is expected to enable ALS patients to gain access to innovative therapies sooner, reflecting the company’s patient‑centered R&D philosophy in the rare‑disease space.

CB03-154 is a next-generation, selective potassium‑channel opener of the voltage‑gated KCNQ2/3, independently discovered and developed by Zhimeng Biopharma, and possesses potential best-in-class properties. By modulating neuronal excitability and restoring the balance between excitation and inhibition, this compound has demonstrated neuroprotective effects on motor neurons in preclinical studies. The completion of enrollment in this pivotal clinical trial marks the entry of a critical phase of validating the efficacy and safety of CB03-154 in patients with ALS.

In terms of clinical development, CB03-154 has been steadily advancing across multiple CNS indications. As of October 2026, in addition to the ALS indication, the drug has already entered the Phase 2 clinical trial for Focal Epilepsy in China and Australia. Furthermore, in June 2026, it received approval from the China CDE to initiate a Phase 2 trial for Major Depressive Disorder (MDD). The concurrent advancement of these three clinical studies fully underscores CB03-154’s broad development potential in the field of central nervous system disorders.

Dr. Huanming Chen, the Founder and CEO of Zhimeng Biopharma, stated: “The completion of patient enrollment for the pivotal Phase 2/3 clinical trial of CB03-154 marks a strategically significant milestone for Zhimeng Biopharma in the field of ALS treatment. I would like to extend my sincere appreciation to Professor Fan Dongsheng and the investigators at all clinical research centers across China for their dedicated efforts, as well as to all ALS patients and their families who participated in the trial for their selfless commitment. Moving forward, we will spare no effort to advance clinical development and regulatory submissions, striving to bring a truly effective new treatment option to ALS patients in China and around the world as soon as possible.”

About Zhimeng

Founded in 2018, Shanghai Zhimeng Biopharma, Inc, is a clinical stage biopharmaceutical company dedicated to the research and development of original small‑molecule drugs. The company focuses on liver diseases and central nervous system disorders, with a strong pipeline targeting treatment options for refractory epilepsy, neuropathic pain, amyotrophic lateral sclerosis (ALS), major depressive disorder (MDD), and other neurological conditions. In addition to its CNS portfolio, Zhimeng Biopharma has also made significant progress in the field of functional cure for chronic hepatitis B; its leading product, ZM‑H1505R (capsid inhibitor), has entered pivotal Phase 3 trial in China.

Disclaimer

This press release contains forward-looking statements. While Zhimeng considers the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

For more information, please visit: www.corebiopharma.com

ScienceOra Demonstrates AI-Assisted Hydrogen-Production Catalyst Design Workflow at Tencent Global Digital Ecosystem Summit

The workflow spans literature analysis, candidate design, experimental planning and industrial decision support, extending AI4S into materials research

SHENZHEN, China, Oct. 31, 2026 /PRNewswire/ — Wenge AI demonstrated an AI-assisted hydrogen-production catalyst design workflow supported by ScienceOra at the 2026 Tencent Global Digital Ecosystem Summit. The demonstration showed how AI for Science (AI4S) can connect literature analysis, catalyst candidate design, experimental planning and industrial decision support, helping materials researchers translate scientific evidence into actionable research plans.

ScienceOra is Wenge AI’s intelligent research decision platform, built on the ScienceOne Scientific Foundation Model. For specialist research tasks such as materials development, the platform brings together scientific models, professional literature, research data and tools to support information access, research-plan development and scientific decision-making.

ScienceOra plans and executes a five-step catalyst design workflow
ScienceOra plans and executes a five-step catalyst design workflow

From literature analysis to catalyst candidate design

The demonstration focused on the design of a high-entropy alloy catalyst for the alkaline hydrogen evolution reaction. To address the need for high activity and durability, ScienceOra searched professional literature and drew on published research methods and elemental properties to support the development of candidate designs. It also cross-checked optimization proposals against relevant literature, providing researchers with references that could be reviewed and verified.

Rather than simply generating material formulations, the workflow connects documentary evidence, materials knowledge and specific design objectives to support more targeted analysis of candidate solutions. Researchers remain responsible for assessing scientific validity and determining subsequent research directions.

From experimental planning to industrial decision support

For experimental planning, ScienceOra can assist in developing research protocols around candidate designs, helping researchers organize experimental variables and producing testing standard operating procedures (SOPs) and related reference information for subsequent validation.

For industrial applications, the platform can also support comparative analysis across dimensions such as the feasibility of scaled hydrogen production, performance at industrially relevant current densities, durability, raw-material availability and compatibility with mass-production synthesis processes. It can then assist in establishing decision priorities, screening criteria and process-improvement recommendations.

Candidate designs, experimental plans, process recommendations and references can be consolidated into a structured research report, helping R&D teams assess scientific evidence alongside engineering constraints. AI provides analytical and decision support, while experimental testing and scientific validation remain essential parts of materials research.

Previously disclosed collaboration reports design efficiency and activity improvements

In a previously disclosed industry–research collaboration on hydrogen-production catalyst design, ScienceOra supported literature analysis and research-plan development. The collaboration reported a 38% improvement in catalyst activity and reduced the design stage from several months to 30 minutes. The case illustrates the potential of domain-specific AI to connect scientific literature, research design and engineering requirements.

ScienceOra was recently made available on Tencent WorkBuddy, with an initial offering of more than 30 research expert agents and skills covering literature analysis, research hypotheses, plan design, modeling and simulation, validation analysis and research communication. The conference demonstration further illustrated how ScienceOra can be applied to specialist materials research, as AI4S moves beyond general information processing toward support for research workflows and industrial R&D decision-making.

For more information, visit https://www.scienceone.ai/portal/.

About Wenge AI

Wenge AI (1956.HK) is a provider of artificial intelligence technology and service platform products for enterprises. With self-developed large models as its core, the company helps enterprises build practical intelligent platforms and applications. Founded by a team of AI scientists from the Chinese Academy of Sciences, Wenge AI has deep technological expertise in large models, cognitive intelligence and complex-system modeling, and is committed to advancing AI from technological capabilities to enterprise-level applications.

PFPFA CEO Jeffrey Chow Wins New Entrepreneur Category at Entrepreneur of the Year Award 2026, Recognised for Business Growth and Entrepreneurial Vision

SINGAPORE, Oct. 31, 2026 /PRNewswire/ — Jeffrey Chow, Chief Executive Officer of PFPFA Pte Ltd (“PFPFA”), has been recognised as a winner in the New Entrepreneur Category at the Entrepreneur of the Year Award 2026, celebrating his entrepreneurial vision and leadership in establishing and growing the Singapore-based financial advisory firm.

PFPFA Pte Ltd Chief Executive Officer Jeffrey Chow (second from right) receives the Entrepreneur of the Year Award 2026 in the New Entrepreneur Category at the award ceremony held on 30 October 2026 in Singapore.
PFPFA Pte Ltd Chief Executive Officer Jeffrey Chow (second from right) receives the Entrepreneur of the Year Award 2026 in the New Entrepreneur Category at the award ceremony held on 30 October 2026 in Singapore.

Since obtaining its financial adviser licence from the Monetary Authority of Singapore (MAS) in 2021, PFPFA has achieved significant business growth under Chow’s leadership. The firm ranked first in Singapore’s Fastest Growing Companies 2025 by The Straits Times and Statista, and 11th in the Financial Times High-Growth Companies Asia-Pacific 2025 ranking. It was also recognised in the Promising Brands category at the Singapore Prestige Brand Award (SPBA) 2024, reflecting its growing market presence and brand recognition in Singapore.

Beyond business growth, Chow has championed a culture where professionalism, client trust and holistic financial planning take precedence over business performance alone. He believes the financial advisory profession must look beyond individual transactions and short-term outcomes to address the interconnected financial decisions people face throughout their lives. This philosophy has shaped PFPFA’s continued investment in the professional development of its Wealth Associates, strengthening advisory capabilities and fostering long-term client relationships.

Reflecting on the recognition, Chow said:

“Entrepreneurship is about seeing what can be done differently and having the conviction to turn that vision into reality. When we started PFPFA, we set out to build a business grounded in the right values, though the journey has not always been easy. This award is a testament to the perseverance and collective efforts of our associates, colleagues and partners, and the trust our clients have placed in us.

For me, entrepreneurship is not simply about building a bigger business. It is about continually challenging established ways of thinking, creating lasting impact and setting a strong example for the future of the financial advisory profession.”

Looking ahead, Chow is determined to redefine conventional approaches to financial advisory, moving beyond a product-centric model towards one built on deeper client relationships, holistic financial planning and long-term value. Through PFPFA, he hopes to help reshape perceptions of the profession, where financial advisers are recognised not merely for the solutions they offer, but for the meaningful role they play in helping individuals and families navigate important financial decisions throughout their lives.

Building on the foundation established in Singapore, Chow has extended his entrepreneurial vision to the wider region as Executive Director and Group Chief Executive Officer of SingWealth Holdings. Under his leadership, the Group has expanded its financial advisory presence into Malaysia and Hong Kong, while recognising the distinct services and regulatory requirements of each market.

Beyond financial advisory, SingWealth continues to develop a broader ecosystem of complementary businesses, connecting different areas of expertise to support the evolving financial and legacy needs of individuals, families and businesses.

About PFPFA Pte Ltd

Established in 2020 and licensed by the Monetary Authority of Singapore (MAS) in January 2021, PFPFA Pte. Ltd. has grown into a well-recognised financial advisory firm in Singapore. Offering a comprehensive suite of services—including investment advisory, insurance solutions, and estate planning and business succession planning—PFPFA is committed to supporting individuals, families, and businesses in making informed long-term financial decisions.

At PFPFA, we believe in fostering lasting relationships built on trust, expertise, and a deep understanding of our clients’ evolving financial goals. With a commitment to excellence and innovation, we empower clients to navigate their financial futures with confidence.

PFPFA Pte Ltd is a wholly owned subsidiary of SingWealth Holdings Pte Ltd.

For more information, visit www.pfp-fa.com.

For more information about SingWealth Holdings Pte Ltd, visit www.singwealthholdings.com.

Chamet Strengthens Multimodal AI Moderation for Live Video Chat as Singapore’s Online Safety Commission Takes Effect

Multi-model risk scoring and multimodal detection of suspected minors help the adults-only platform find and act on harmful content in real time

SINGAPORE – Media OutReach Newswire – 31 October 2026 – Chamet, a global live streaming and video chat platform with more than 50 million downloads on Google Play worldwide, is expanding its use of multimodal, multi-model AI to moderate live content and protect users. Southeast Asia is one of Chamet’s strongest regions, and its safety systems are built for live video.

Singapore has moved quickly on online harms. The Online Safety Commission began operations on June 29, 2026, and can direct platforms to disable harmful content or restrict accounts in cases such as online harassment and intimate image abuse. Since March 31, 2025, IMDA’s online safety code for app stores has required designated app stores to roll out age assurance that keeps children away from apps rated 18+.

Multimodal Detection of Suspected Minors

Chamet is open only to adults aged 18 and over, with zero tolerance for underage users. Rather than relying on one signal, its system combines profile photos, live-stream frames, video, voice, text, self-reported age and account behaviour. Each case receives a risk level based on model confidence, and the system can restrict content, limit interactions, or restrict the account. Human reviewers check cases before final decisions. Accounts found to have falsified their age are permanently suspended.

Multi-Model Fusion for Content Review

Chamet runs several moderation models and third-party services, each with its own labels and confidence scales. The platform maps their outputs onto one shared risk scale, then weighs them by content type, where the content appears, and each model’s track record. Each item gets one risk level, and a consistent action, with the highest-risk cases reviewed first.

These systems work alongside real-person face verification, safeguards against unauthorised screen recording, in-app reporting and blocking, and an appeals process. Chamet also offers free real-time AI translation in more than 50 languages, turning speech into on-screen subtitles during video calls.

“In a live video call, harm can happen in seconds, so safety has to work just as fast,” said David Qi, Chief Marketing Officer of Chamet. “By combining many models and signals, our review teams can spot risk sooner and make more consistent decisions. Connecting people and keeping them safe are two parts of the same job.”

Hashtag: #Chamet

The issuer is solely responsible for the content of this announcement.

About Chamet

Chamet is a global live streaming and video chat platform open only to adults aged 18 and over. It offers live streaming, video chat, party rooms, and feeds for social discovery. AI-powered real-time translation helps people talk across languages, while community guidelines, AI-assisted and human moderation, and in-app report and block tools support . Learn more at .

Chamet is owned and operated by FULIAO HONG KONG LIMITED (HK Fuliao), a Hong Kong-based technology company. HK Fuliao provides the development, localisation, content management, customer service and operations behind Chamet. Learn more at .

OCI Announces EGM Approval and Updated Indicative Timetable for Orascom Construction Combination

AMSTERDAM, Oct. 31, 2026 /PRNewswire/ — OCI N.V. (“OCI” or the “Company“) (Euronext: OCI) today announced that its shareholders have approved all resolutions relating to the proposed business combination between OCI and Orascom Construction PLC (“Orascom Construction“) (the “Combination“). OCI also provides shareholders with an updated indicative timetable for the Combination, including the expected delisting date for OCI Shares from Euronext Amsterdam.

Shareholder Information and Key Dates

  • Today, the Extraordinary General Meeting approved all resolutions put to a vote, including the resolutions relating to the Combination and the OCIN Sale. Each resolution was also supported by a majority of votes cast by minority shareholders. The detailed voting results are available on OCI’s website in accordance with applicable requirements.
  • Euronext Amsterdam has approved the delisting of the OCI Shares effective as of 27 November 2026, resulting in the final day OCI Shares can be traded on Euronext Amsterdam being 26 November 2026, subject to receipt of the required regulatory approvals in the relevant jurisdictions, and any other developments that may affect the delisting date. The ex-date for the Distribution of OC Shares to OCI shareholders is expected to be 27 November 2026.
  • The Tender Closing Date under NNS’s voluntary offer (the “Offer“) is 17 November 2026 at 17:40 CET. Shareholders wishing to tender their OCI Shares should contact their bank, broker or other intermediary sufficiently in advance, as intermediaries may apply earlier instruction deadlines. Further updates regarding the Offer, including on the expected timetable of relevant events relating to the Offer, are expected to be made by NNS with due observance of applicable rules and regulations.
  • Subject to completion of the required corporate, regulatory, listing and settlement steps, and subject to further announcements by NNS on the timetable for the Offer, OCI currently expects the crediting of Orascom Construction shares (“OC Shares“) to eligible shareholder accounts to commence on or around 8 December 2026. The date on which an individual shareholder receives OC Shares may differ, potentially significantly, depending on the shareholder’s circumstances, the completeness of settlement information provided, and the processes of the relevant intermediary.
  • The timetable for the Combination continues to be indicative. OCI will keep its shareholders informed as further information becomes available, including but not limited to as information on the Offer is made public by NNS in accordance with the relevant statutory notice requirements.

 

Indicative Timetable

The table below sets out certain expected key dates and times in connection with the Combination. Except where otherwise indicated, all dates and times are indicative only, reflect the Company’s current expectations and remain subject to change. Capitalised terms not otherwise defined in this press release have the meanings given to them in the EGM Circular or, as applicable, NNS’s Offer Memorandum.

 

Event

Expected time and date

Explanation

Expected effectiveness of the Demerger

2 November 2026

Following approval of the
relevant resolutions at the
EGM, effectiveness of the
Demerger remains
subject to execution of the
demerger deed. On 20
October 2026, OCI
received confirmation
from the Amsterdam
District Court that no
creditor had filed an
objection against the
Demerger.

Tender Closing Date under the Offer

17 November 2026 at
17:40 CET

Shareholders should
contact their bank, broker
or other intermediary
sufficiently in advance, as
intermediaries may apply
earlier instruction
deadlines.

Post-Closing Acceptance Period

To be determined and announced by NNS, together with other
relevant dates regarding the Offer. The record date for the
Distribution will not be set prior to the settlement of the Post-
Closing Acceptance Period.

Expected final trading day in OCI Shares

26 November 2026

Expected last day on
which OCI Shares will
trade with entitlement to
the Distribution.

Expected ex-date for the Distribution and
delisting of OCI Shares from Euronext
Amsterdam

27 November 2026

Euronext Amsterdam has
approved the delisting of
the OCI Shares effective
as of 27 November 2026.
The ex-date for the
Distribution is expected to
be 27 November 2026.

Expected record date for the Distribution

Currently expected to be
30 November 2026,
subject to the timetable for the Post-Closing
Acceptance Period and its
settlement

The record date will not
occur before settlement of
the Post-Closing
Acceptance Period. If the
Offer timetable is
extended, the record date
and subsequent
Combination milestones
will be adjusted
accordingly.

Expected commencement of crediting
OC Shares to eligible shareholder
accounts

On or around 8 December
2026, subject to the
timetable for the Post-
Closing Acceptance
Period and its settlement

 

Reflects the current
operational estimate for
intermediaries to begin
crediting OC Shares to
eligible shareholders’
securities accounts
following the Distribution,
subject to the timetable
for the Offer and
settlement of the Post-
Closing Acceptance
Period. The date on which
an individual shareholder
receives OC Shares may
differ, potentially
significantly, depending
on the intermediary
involved and the
completeness and
validation of the relevant
settlement information.

Funding of Dutch dividend withholding
tax

To be determined

As described below and
in the EGM Circular, OCI
will sell a number of OC
Shares to fund the Dutch
dividend withholding tax
payable in connection
with the Distribution.
Completion of the sale will
not be a condition
precedent to OCI making
the Distribution.

Expected commencement and
implementation of the dissolution and
liquidation process of OCI

December 2026 – H1 2027

Dissolution of OCI will not
occur prior to the delisting
of the OCI Shares.

 

Additional Information Regarding the Distribution

Subject to completion of the Combination, the OC Shares will be distributed to eligible OCI shareholders in accordance with the transaction structure described in the EGM Circular. Shareholders who are eligible to receive OC Shares but whose complete or validated settlement information has not been provided (by them or, as applicable, their bank or broker) by the relevant operational deadlines may not receive their OC Shares at the same time as other shareholders. Their entitlements will instead be handled in accordance with the applicable suspense arrangements described in the EGM materials.

OCI encourages shareholders to read the ‘Shareholder Decision Guide’ and the other information regarding the Combination available on OCI’s website. The Shareholder Decision Guide advises shareholders wishing to receive OC Shares to contact their bank, broker or custodian as soon as possible to confirm whether, and subject to what conditions, that intermediary supports the Distribution. The indicative timetable  assumes that OCI Shares validly tendered during the Offer Period or Post-Closing Acceptance Period will settle under the Offer before the record date for the Distribution. If the Offer timetable is longer than currently assumed, including if NNS determines that the Post-Closing Acceptance Period will continue for two weeks, the timetable for implementation of the Combination will be adjusted accordingly.

 

Additional Information Regarding Dutch Dividend Withholding Tax

As described in the EGM Circular, OCI will sell a number of OC Shares corresponding to the percentage of the total value of the Distribution to be withheld on account of Dutch dividend withholding tax. Because the number of OC Shares to be sold will be determined by reference to the applicable withholding percentage, the number of OC Shares distributed to shareholders will not depend on whether the proceeds of the sale are sufficient to cover the Dutch dividend withholding tax payable.

Completion of the sale of such OC Shares will not be a condition precedent to OCI making the Distribution and is not expected to delay or otherwise affect the timing of the Distribution to shareholders.

If the proceeds of such sale are insufficient to cover the Dutch dividend withholding tax payable in connection with the Distribution, the shortfall will be funded for the account of the combined company. No additional OC Shares will be withheld from relevant shareholders solely as a result of such shortfall.

 

Important Notice Regarding Timing

If any of the dates and/or times set out in the indicative timetable change, OCI will provide notice of such changes by means of a press release and will announce final dates in accordance with applicable laws, regulations and stock exchange requirements. The actual timetable may differ, including significantly, from the timetable set out above.

The timing of the Offer, including the commencement, duration and closing of the Post-Closing Acceptance Period, remains subject to determinations made by NNS in accordance with the terms of the Offer. Changes to Offer-related milestones may impact the timing of subsequent steps in the process.

Except for events directly related to the Offer, the occurrence and timing of the milestones described above remain subject to the remaining conditions and implementation steps applicable to the Combination, including implementation of the Combination by the long-stop date of 30 December 2026.

 

 

 

Annex: Voting results Extraordinary General Meeting of Shareholders OCI Global 30 October 2026

A total of 155,679,306 shares were present or represented at the AGM. These shares represent approximately 73.79% of the votes that can be cast at the AGM. The voting items were approved as follows:

Agenda item 3: Proposal to adopt the Combination Resolutions 

For 

Against 

Abstain 

Total 

Total votes 

154,609,658

237,215

832,433

155,679,306

% of total votes (excl. abstentions) 

99.85 %

0.15 %

% of free float (excl. abstentions) 

98.32 %

1.68 %

 

Agenda item 4: Proposal to grant approval to the OCIN Sale 

For 

Against 

Abstain 

Total 

Total votes 

154,572,142

241,416

865,748

155,679,306

% of total votes (excl. abstentions) 

99.84 %

0.16 %

% of free float (excl. abstentions) 

98.29 %

1.71 %

Free float percentages relate only to free float shares present or represented at the EGM (approximately 21% of total free float) and exclude Family shares. Rows marked “excl. abstentions” exclude abstentions from the percentage calculation.

 

 

ABOUT OCI GLOBAL

Learn more about OCI at www.oci-global.com. You can also follow OCI on LinkedIn.

SMTC Recognized with Frost & Sullivan’s 2026 North America Company of the Year Recognition for Mid-tier Electronic Manufacturing Services

SMTC is redefining the value of a mid-sized EMS partner by combining responsive customer engagement, Tier 1 capabilities, and a resilient North American operating network.

SAN ANTONIO, Oct. 31, 2026 /PRNewswire/ — As original equipment manufacturers (OEM) place greater emphasis on supply chain resilience, regionalized production, and faster response to changing market conditions, the role of electronic manufacturing services (EMS) providers is evolving. Frost & Sullivan recognizes SMTC with the 2026 North America Company of the Year Recognition in the Mid-tier Electronic Manufacturing Services industry for its strong performance across strategy effectiveness and strategy execution. SMTC’s ability to work directly with customer decision-makers from the outset enables faster action, collaborative problem-solving, and closer alignment throughout engagements. This customer-centric approach, combined with a strategically positioned North American operating network and broad end-to-end manufacturing capabilities, strengthens the company’s ability to respond to complex customer requirements while supporting speed, flexibility, and supply chain continuity.

“SMTC differentiates itself from competitors by combining the flexibility and responsiveness of a smaller EMS company with many of the capabilities typically associated with a larger Tier 1 company. A key part of this advantage comes from its ability to work directly with customer decision-makers from the outset, which supports faster action, more collaborative problem-solving, and closer alignment throughout the engagement,” said Sujan Sami, Senior Research Director, Frost & Sullivan.

SMTC’s strategy is built around providing customers with comprehensive manufacturing support while maintaining the agility needed to respond to changing market conditions. Headquartered in Melbourne, Florida, the company provides a abroad manufacturing footprint across North America and supports customers in aerospace/defense/security, medical and life sciences, advanced computing, robotics, and power and smart infrastructure. Its end-to-end capabilities encompass new product introduction (NPI), printed circuit board assembly, systems integration, testing, supply chain management, and other higher-value manufacturing services.

Innovation and operational flexibility remain central to SMTC’s approach. The company supports customers through complex production requirements, including factory transfers, operational transitions, and tariff-related supply chain decisions. Its ability to combine high-touch customer engagement with manufacturing depth allows customers to access the personalized support of a mid-sized provider without sacrificing the capabilities required for complex programs.

“We are honored to receive this award for the third year in a row. Our team members work tirelessly to exceed our customer’s expectations with excellence every minute of every day. It is through teamwork and collaboration, built on our purpose to enhance people’s lives and our world every day, that drives us to deliver in partnership with our customer needs”, said Mike Buseman, CEO at SMTC.

SMTC’s North American operating network further strengthens its competitive position. The company’s footprint includes manufacturing facilities, procurement and logistics centers, return merchandise authorization (RMA), refurbish and repair centers, design and engineering centers, wire cable and harnesses, and a metal fabrication center across key regions. This integrated model helps reduce handoffs, support smoother production transfers, and create greater continuity from product introduction through fulfillment and repair. SMTC can also shift production between sites, adjust capacity as demand changes, and help customers move manufacturing closer to key end markets.

Beyond manufacturing execution, SMTC creates customer value through value engineering, supply chain expertise, and disciplined production processes. Its capabilities are designed to reduce lead times and material costs, improve assembly efficiency, strengthen test coverage, and minimize scrap, rework, and field failures. Structured NPI processes, project simulations, stage gates, and Customer Focus Teams provide customers with greater visibility and support throughout the transition from concept to production.

The company’s approach also contributes to strong customer relationships. SMTC emphasizes transparent communication, responsiveness, and partnership throughout the manufacturing lifecycle, with many customer relationships extending for more than 20  years. This longevity demonstrates the value customers place on SMTC’s ability to provide dependable support, address challenges with urgency, and adapt alongside evolving production requirements.

Frost & Sullivan commends SMTC for establishing a differentiated position within the mid-tier electronic manufacturing services industry. By combining customer intimacy and responsiveness with Tier 1 capabilities, a resilient North American footprint, and comprehensive manufacturing expertise, the company is well positioned to help OEMs navigate increasingly complex supply chain and production environments.

Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The award recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices Recognition

Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.

Contact:
Ashley Shreve
E: ashley.weinkauf@frost.com

About SMTC

SMTC Corporation was founded in 1985. SMTC is a mid-size provider of end-to-end electronics manufacturing services (EMS) including PCBA production, systems integration and comprehensive testing services, enclosure fabrication, as well as product design, sustaining engineering and supply chain management services. SMTC has facilities and offices in the United States, Mexico, Asia and Canada. Services extend over the entire electronic product life cycle from the development and introduction of new products through to the growth, maturity and end-of-life phases.

Contact: Scott Smith
E. Scott.Smith@smtc.com

QNET’s Bernhard H. Mayer® Brings Emerging Design Talent Into Swiss Watchmaking

Egyptian student wins inaugural Open Innovation Challenge with VELORA, a watch concept set for production with a portion of sales proceeds supporting a breast cancer organisation in Egypt

HONG KONG, Oct. 31, 2026 /PRNewswire/ — Bernhard H. Mayer®, QNET‘s Swiss luxury brand for fine jewellery and timepieces, has named Egyptian design student Fatema Tarek El Sayed the winner of its inaugural Bernhard H. Mayer® Open Innovation Challenge. Her winning concept, VELORA, will be developed into a Bernhard H. Mayer® timepiece, connecting emerging design talent with Swiss watchmaking expertise and support for women affected by breast cancer.

QNET’s Bernhard H. Mayer® Brings Emerging Design Talent Into Swiss Watchmaking
QNET’s Bernhard H. Mayer® Brings Emerging Design Talent Into Swiss Watchmaking

Fatema, a student at the Faculty of Arts and Design at October University for Modern Sciences and Arts in Egypt will travel to Biel, Switzerland, as part of her prize. She will gain first-hand exposure to Swiss watchmaking and work alongside the brand’s experts as her concept is adapted for production. The finished timepiece is set to be unveiled in October 2027, with a portion of sales proceeds supporting a breast cancer organisation in Egypt.

Launched in October 2025 as part of the brand’s Pink October breast cancer awareness initiative, the challenge invited young designers across the Middle East and North Africa (MENA) region to create an original watch concept inspired by hope, strength, and compassion for women affected by breast cancer. In collaboration with arts and design institutions across the region, Bernhard H. Mayer® offered students an opportunity to develop with the potential to become a finished timepiece.

Mattias Mildenborn, Chief Executive Officer of QNET, said, “Fatema’s achievement shows the value of connecting emerging talent with industry expertise across borders. Through Bernhard H. Mayer®, we can give a young designer the opportunity to develop her idea with Swiss watchmaking specialists and see it become a finished timepiece. This challenge reflects our belief that business can create opportunities for people while supporting a meaningful cause.”

The initiative reflects Bernhard H. Mayer®‘s commitment to preserving its watchmaking heritage while encouraging a new generation of designers. By bringing students into contact with experienced watchmaking specialists, the challenge connects creative education with practical product development.

VELORA draws its inspiration from the metamorphosis of a moth emerging from its cocoon, a symbol Fatema connected to the experiences of women who have faced breast cancer.

Fatema said: “What I am most proud of is that this project taught me that design can communicate something beyond its appearance; it can carry a message, create an emotional connection, and give meaning to an experience of resilience. Winning this challenge is an incredible honour, and I am excited to see where this idea takes me and to learn from the world of Swiss watchmaking.”

Dr. Tarek Saleh, Dean of the Faculty of Arts and Design at October University for Modern Sciences and Arts, said: “We are immensely proud of Fatema. Opportunities like this allow students to move beyond academic projects and experience what it means to develop a design with a real brief, a real audience, and a real purpose. Seeing her concept move towards becoming an actual timepiece is an exceptional experience for both Fatema and our institution.

Fatema’s achievement was celebrated at an event in Cairo, Egypt, attended by representatives from Bernhard H. Mayer®, QNET, academia and the creative community.

The Bernhard Open Innovation Challenge has also received international recognition, winning two Bronze Stevie Awards in the categories of Most Innovative Social Impact and Most Innovative Achievement in Corporate Social Responsibility.